Form 4: Myriad Genetics COO Samraat S. Raha Reports Stock Transactions

Chief Operating Officer of Myriad Genetics, Samraat S. Raha, reports acquisition and disposal of company stock, including restricted stock units and shares withheld for tax obligations.

Summary

• Samraat S. Raha, the Chief Operating Officer of Myriad Genetics, reported transactions involving the company's common stock.
• On March 13, 2025, Raha acquired 216,495 shares of common stock at $0, representing time-based restricted stock units.
• These restricted stock units vest in three equal annual installments starting on the first anniversary of the grant date.
• On March 14, 2025, 7,649 shares were disposed of at a price of $10.07, to cover tax withholding obligations related to the vesting of restricted stock units.
• Following these transactions, Raha beneficially owns 481,240 shares of Myriad Genetics common stock.

Sentiment

Score: 5

Explanation: The document is a routine regulatory filing detailing stock transactions by a company insider. It doesn't inherently convey positive or negative sentiment.

Future Outlook

The restricted stock units vest in three equal annual installments beginning on the first anniversary of the grant date, suggesting future stock acquisitions.

Industry Context

Form 4 filings are standard practice for company insiders to report transactions in their company's stock, providing transparency to the market.

Stakeholder Impact

• The filing provides transparency to shareholders regarding insider transactions.
• The transactions may have a minor impact on the stock price.

Key Dates